Hematology — Medicare Part B billing by state
5 physician groups whose primary specialty is Hematology billed $0.01B to Medicare fee-for-service in 2023.
Calendar year 2023 · Medicare fee-for-service Part B
You're viewing calendar year 2023. State market links open the latest data year.
| State | Groups | Services | Beneficiary-episodes | Medicare payments | Standardized payments ↓ | Payments / group | Services / group |
|---|---|---|---|---|---|---|---|
| California | 3 | 465,424 | 13,164 | $8,192,285 | $8,102,715 | $2,730,762 | 155,141 |
| Pennsylvania | 1 | 108,556 | 7,928 | $2,461,370 | $2,476,576 | $2,461,370 | 108,556 |
| New Jersey | 1 | 130,424 | 2,347 | $576,387 | $548,845 | $576,387 | 130,424 |
Need this specialty's market in one document?
Notify me at launchEach group carries one specialty label — the specialty most common among its clinicians in CMS's Doctors and Clinicians register — so every figure on this page counts groups, not individual clinicians. An organization's entire Medicare billing is credited to that one label, so a specialty's totals reflect how organizations are labeled, not the specialty of each service; large multi-specialty organizations — where no single specialty is a majority of the clinicians — account for much of the volume shown under many specialties. Totals include only volume that can be credited to a single group; clinicians registered with more than one group are left out of group totals and shown as “—” elsewhere on Nevvi. Clinicians not registered with any group, and groups without a specialty label, are also not included. A group is counted in every state its clinicians bill Medicare from, so state figures overlap and never sum to the national figure.
All figures are Medicare fee-for-service Part B only; Medicare Advantage claims are not included. Cross-state comparisons use standardized payments, which remove regional differences in what Medicare pays; services without a standardized amount — mainly Part B drugs — are not in that column, and the Medicare payments column shows what Medicare actually paid. Beneficiary counts are beneficiary-episodes: one person treated in more than one setting or state is counted in each.
Top codes by Medicare payments CY2023
| Code | Services | Medicare payments ↓ | Largest state markets |
|---|---|---|---|
| J0897 · Injection, denosumab, 1 mg | 104,763 | $1,912,430 | CAPANJ |
| J9271 · Injection, pembrolizumab, 1 mg | 41,200 | $1,759,171 | CAPANJ |
| J1569 · Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 24,000 | $858,016 | CAPANJ |
| 78815 · Nuclear medicine study from skull base to mid-thigh with ct scan | 605 | $827,840 | CAPANJ |
| 99214 · Established patient office or other outpatient visit, 30-39 minutes | 7,752 | $765,456 | CAPANJ |
| J9299 · Injection, nivolumab, 1 mg | 26,400 | $574,899 | CAPANJ |
| 96413 · Administration of chemotherapy into vein, 1 hour or less | 4,912 | $542,592 | CAPANJ |
| J9352 · Injection, trabectedin, 0.1 mg | 1,401 | $368,673 | CAPANJ |
| A9595 · Piflufolastat f-18, diagnostic, 1 millicurie | 621 | $301,691 | CAPANJ |
| 99215 · Established patient office or other outpatient visit, 40-54 minutes | 1,781 | $252,556 | CAPANJ |
| Q5106 · Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units top by services | 18,240 | $111,306 | CAPANJ |
| J1439 · Injection, ferric carboxymaltose, 1 mg top by services | 71,250 | $62,421 | CAPANJ |
| Q0138 · Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) top by services | 154,020 | $58,585 | CAPANJ |
| J2469 · Injection, palonosetron hcl, 25 mcg top by services | 14,770 | $12,225 | CAPANJ |
| J9263 · Injection, oxaliplatin, 0.5 mg top by services | 63,260 | $3,530 | CAPANJ |
| J1100 · Injection, dexamethasone sodium phosphate, 1 mg top by services | 31,288 | $3,013 | CAPANJ |
Every code above is searchable free at full depth. Ranking organizations across several codes at once — one combined market view — is part of a Nevvi subscription.
Notify me at launch